SpyGlass Pharma's BIM-IOL System Shows 42% IOP Reduction at 24 Months in Glaucoma Patients
核心洞察
SpyGlass Pharma (搜索)'s BIM-IOL System demonstrated a statistically significant 42% reduction in mean intraocular pressure from baseline at 24 months (p<0.0001) in patients with open-angle glaucoma or ocular hypertension.
All patients (100%) were completely off topical IOP-lowering medications at 24 months while maintaining excellent visual acuity of 20/30 or better.
The system combines bimatoprost-releasing drug pads with an intraocular lens implanted during routine cataract surgery, potentially transforming glaucoma care by eliminating daily eye drops.
SpyGlass Pharma (搜索) announced compelling 24-month interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), showing a statistically significant 42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001). The innovative system achieved complete elimination of topical medications in all patients while maintaining excellent visual outcomes.
Sustained IOP Control Without Daily Medications
The single-center, prospective first-in-human trial evaluated the BIM-IOL System in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery. At 24 months, mean IOP decreased from 25.1 ± 2.5 mmHg at baseline post-washout to 14.5 ± 3.0 mmHg, with no statistically significant difference in IOP reduction across the three dosage groups tested.
Remarkably, 100% of patients were off all topical IOP-lowering medications at 24 months, addressing one of the most persistent challenges in glaucoma management. "Adherence with daily topical IOP-lowering medications is one of the most consistent challenges for patients in the management of glaucoma and ocular hypertension," said Malik Kahook, M.D., Co-founder of SpyGlass Pharma (搜索).
Excellent Visual Outcomes and Safety Profile
All treated patients achieved 20/30 or better Best Corrected Distance Visual Acuity (BCDVA) at 24 months, demonstrating that the system maintains the primary benefit of cataract surgery while providing sustained glaucoma treatment. The BIM-IOL System was well-tolerated, with all observed adverse events considered related to the cataract procedure rather than the device itself. No serious adverse events were observed.
Phase I/II Trial Confirms Efficacy
Complementary data from a Phase I/II multicenter, randomized, double-masked, controlled trial involving 104 patients further validated the system's effectiveness. Patients were randomized 2:1:1 to receive either the 78 mcg BIM-IOL System (n=51), the 39 mcg BIM-IOL System (n=23), or a control group with standard monofocal IOL plus twice-daily timolol drops (n=30).
At three months, patients achieved a 37% and 36% reduction in mean IOP from baseline in the 78-mcg and 39-mcg dose groups, respectively, compared to a 37% reduction in the control group. Importantly, 98% of patients in the 78-mcg dose group and 96% of patients in the 39-mcg dose group were free from all topical IOP-lowering medications.
Jeffrey Kammer, MD, associate professor of ophthalmology at Vanderbilt University Medical Center and an investigator in the phase I/II trial, noted, "The implantation procedure during routine cataract surgery is straightforward, and the three-month IOP reduction results and improved visual performance are highly compelling."
Technology and Clinical Pathway
The BIM-IOL System comprises novel, proprietary non-bioerodible drug pads attached to SpyGlass Pharma (搜索)'s intraocular lens, designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved by the FDA in 2001 for IOP reduction. The system leverages an implantation technique familiar to all cataract surgeons, including the two-thirds of physicians who do not routinely perform minimally invasive glaucoma surgery.
"With an implantation technique familiar to all cataract surgeons, including the two-thirds of physicians who do not routinely perform minimally invasive glaucoma surgery, we believe our system has the potential to become a widely-implemented solution for reducing reliance on topical medication," said Patrick Mooney, Chief Executive Officer of SpyGlass Pharma (搜索).
SpyGlass Pharma (搜索) is planning initiation of two registrational Phase III clinical trials of the BIM-IOL System by end of year and continues long-term follow-up of patients in its first-in-human trial. The company plans to work with the FDA to advance the program through Phase III clinical trials, New Drug Application (NDA) submission, and ultimately to potential commercial approval.